IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Oliver Yoa-Pu HU et al.

Serial No: TO BE ASSIGNED

Filed: February 22, 2002

For: Cytochrome P450 3A Inhibitors and Enhancers

Art Unit: TOOBE ASSI

Attorney Docket: 39297

Examiner: TO BE ASSIGNED

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §1.56, 1.97, and 1.98

Honorable Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

In compliance with the dictates of 37 C.F.R. § 1.56, 1.97, and 1.98, Applicant hereby submits an Information Disclosure Statement. The attached listing is submitted with the desire that the Examiner considers the information and that the references considered be printed on any resulting patent. It is respectfully requested that the Examiner indicate such consideration by enclosing an appropriately initialed copy of the enclosed form PTO-1449 with the next communication from the Patent Office.

The Commissioner is hereby authorized to charge payment of any additional fees due or credit any overpayment to Deposit Account No. 22-0261.

Respectfully submitted,

- Fw Chas

Fei-Fei Chao, Ph.D. Attorney of Record Reg. No. 43,538

Date: February 22, 2002

Venable, Baetjer, Howard & Civiletti, L.L.P. 1201 New York Avenue, N.W., Suite 1000 Washington, D.C. 20005 (202) 216-8011

DCDocs2/353961